The plasmid DNA manufacturing market is expected to grow at a CAGR of 21% over the forecast period 2021 to 2027 and to reach valuation of around US$ 320 million by 2027.
The plasmid DNA manufacturing market is expected to grow at a CAGR of 21% over the forecast period 2021 to 2027 and to reach valuation of around US$ 320 million by 2027.
The report provides size (in terms of volume and value) of Plasmid DNA manufacturing market for the base year 2020 and the forecast between 2020 and 2027. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Plasmid DNA manufacturing market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Plasmid DNA manufacturing market development in United States, Europe and China.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/34955
Increasing Number of Patients Opting for Gene Therapy
Plasmid (pDNA) DNA plays a major role in modern healthcare, as it is used directly as a therapeutic agent in gene therapy or generation of vaccine antigens. Furthermore, pDNA is used as a master-template product to support production of new and emerging biopharmaceutical products and processes including RNA, in-vitro protein production, and cell therapies.
Increasing number of patients opting for gene therapy is expected to propel growth of plasmid DNA manufacturing market
Increasing number of patients opting for gene therapy is a major factor driving growth of the plasmid DNA manufacturing market. Gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various diseases.
For instance, Adeno-associated AAV2 vectors carrying therapeutic gene (RPE65) intra-retinal injection leads to improved vision of individuals suffering from Leber’s Congenital Amaurosis.
Several clinical trials are being conducted on viral vectors and plasmid DNA manufacturing that are focused on the potential of gene therapy. Increasing investments in drug development and commercialization of these therapies in order to meet significant medical needs are factors driving the market growth. These genetic markers are associated with complex diseases, therefore it is important to study about the genetic information and its clinical application in designing clinical trials and gene therapy product manufacturing.
Some of the key players operating in the report are Akron Biotech, Cobra Biologics Limited, VGXI, Inc., Aldevron, PlasmidFactory GmbH & Co. KG, LakePharma, Inc., Delphi Genetics, Waisman Biomanufacturing, Richter-Helm BioLogics, Eurogentec, Kaneka Corporation, Nature Technology Corporation, and Cell and Gene Therapy Catapult.
Enquire here Before Buying Report@ https://www.visionresearchreports.com/report/enquiry/34955
Segment Insights
Gene therapy accounts for the largest share of global plasmid DNA manufacturing market.
The market in North America is expected to contribute major revenue share in the global plasmid DNA manufacturing market. The market for plasmid DNA manufacturing in North America is driven by rapid technological advancements and R&D activities in the healthcare sector. In addition, presence of several biopharmaceutical manufacturers in the US coupled with a strong and effective regulatory structure for development of advanced therapies in the country is boosting the growth of this market in North America. Besides this, recent approval of gene therapies by US FDA is projected to augment the demand for plasmid DNA manufacturing in coming years.
The market in Asia Pacific is expected to witness faster growth in the global plasmid DNA manufacturing market. This can be attributed to the increasing government expenditure on development of healthcare infrastructure in the region. In addition, the growing government initiatives and increased investments by private companies related to R&D activities are likely to fuel this regional market.
Europe is expected to witness substantial growth in the market for plasmid DNA manufacturing. Factors that are expected to drive the growth in European market are significant incentives offered through Orphan Medicinal Products Regulations (European Union) that has encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable endeavor.
Market Segmentation
By Application
- Gene Therapy
- Vaccinology
By Disease
- Infectious Disease
- Cancer
- Genetic Disorder
By End use
- Research Institute
- Biotech Companies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Research Report@ https://www.visionresearchreports.com/report/cart/34955
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333